Modulating ramp activity

Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S325000

Reexamination Certificate

active

06927317

ABSTRACT:
The invention provides genetically-modified non-human mammals and genetically-modified animal cells containing a disrupted RAMP1, RAMP2, or RAMP3 gene. Also provided by the invention are methods of screening for agents that modulate the activity or expression of a RAMP and methods of treating mammals to modulate liver function and/or muscle metabolism.

REFERENCES:
http://www.bioscience.org/knockout/knochome.htm ; 1998.
Pera, 2000, Journal of Cell Science, vol. 113, pp. 5-10.
Chapman, 1989, PNAS, vol. 86, pp. 1292-1296.
Leonard, 1995, Immunological Reviews, vol. 148, pp. 97-114.
Griffiths, 1998, Microscopy Research and Technique, vol. 41, pp. 344-358.
Capecchi, 1994, Scientific American, vol. 270, pp. 34-41.
Hussman, 2000, Mol. Cell. Endocrin., vol. 162, pp. 35-43.
Dinnyes, 2002, Cloning and Stem Cells, vol. 4, pp. 81-90.
Campbell and Wilmut, 1997, Theriogenology, vol. 47, pp. 63-72.
Kent-First, 2000, Nature Biotecnology, vol. 18, pp. 928-929.
Denning, 2001, Nature Biotechnology, vol. 19, pp. 559-562.
Partial European Search Report under Rule 46(1), European Patent Office, Application No. EP 01 30 9928, May 10, 2002.
Foord, Steven M., and Marshall, Fiona H., “RAMPs: accessory proteins for seven transmembrane domain receptors”, Trends in Pharmacological Sciences, Elsevier Trends Journal, May 1, 1999, vol. 20, No. 5, pp. 184-187.
McLatchie, Linda M. et al., “RAMPS regulate the transport and ligand specificity of the calcitonin-receptor-like receptor”, Nature, MacMillan Journals, Ltd., May 28, 1998, vol. 393, pp. 333-339.
Derst, C. et al., “Genomic structure and chromosome mapping of human and mouse RAMP genes”, Cytogenics and Cell Genetics, vol. 90, No. 1-2, 2000, pp. 115-118.
Zumpe, Emma T. et al., “Multiple Ramp Domains Are Required for Generation of Amylin Receptor Phenotype from the Calcitonin Receptor Gene Product”, Biochemical and Biophysical Research Communications, vol. 267, No. 1, Jan. 7, 2000, pp. 368-372.
Armour, Susan L. et al., “Pharmacological characterization of receptor-activity-modifying proteins (RAMPS) and the human calcitonin receptor”, Journal of Pharmacological and Toxicological Methods, vol. 42, No. 4, Dec. 1999, pp. 217-224.
Frayon, Stéphane et al., “Dexamethasone Increases RAMP1 and CRLR mRNA Expressions in Human Vascular Smooth Muscle Cells”, Biochemical and Biophysical Research Communications, vol. 270, No. 3, Apr. 21, 2000, pp. 1063-1067.
Kuwasako, Kenji et al., “Visualization of the Calcitonin Receptor-like Receptor and Its Receptor Activity-modifying Proteins during Internalization and Recycling”, Journal of Biological Chemistry, vol. 275, No. 38, Sep. 22, 2000, pp. 29602-29609.
Tilakaratne, Nanda et al., “Amylin Receptor Phenotypes Derived from Human Calcitonin Receptor/RAMP Coexpression Exhibit Pharmacological Differences Dependent on Receptor Isoform and Host Cell Environment”, Journal of Pharmacology and Experimental Therapeutics, vol. 294, No. 1, Jul. 2000, pp. 61-72.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Modulating ramp activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulating ramp activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulating ramp activity will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3457445

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.